Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

Go back to Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
Enliven Marketing Technologies Corporation (NASDAQ: ENLV) Delayed: 1.10 -0.06 (5.17%)
Previous Close $1.16    52 Week High $0.94 
Open $1.15    52 Week Low $0.47 
Day High $1.16    P/E N/A 
Day Low $1.02    EPS $-0.11 
Volume 252,142